Sunnetcioglu, A.Berkoz, M.Yildirim, M.Bora, G.Yalin, S.2025-05-102025-05-1020200030-998210.47391/JPMA.2502-s2.0-85100326394https://doi.org/10.47391/JPMA.250https://hdl.handle.net/20.500.14720/5428Objective: The aim of this study was to assess the influence of plasminogen activator inhibitor-1 (PAI-1) 4G/5G or tissue plasminogen activator (tPA) I/D polymorphisms in chronic obstructive pulmonary disease (COPD) cases in a sample of Turkish population. Methods: PAI-1 4G/5G and tPA Alu-repeat I/D genetic polymorphisms in 153 COPD subjects and 160 controls were investigated using PCR-RFLP and PCR methods, respectively. Results: 4G allele frequency was 0.62 and 0.39 for COPD and control groups, respectively. 4G allele had an estimated 2.56-fold [95% CI = 1.85-3.53] increased risk of COPD. tPA I allele frequency was 0.55 and 0.50, for COPD and control groups, respectively. I allele had an estimated 1.19-fold [95% CI = 0.87-1.62] increased risk of COPD Conclusions: PAI-1 4G/4G and 4G/5G genotypes seemed to play a key role in the pathophysiology of COPD in Turkish individuals. © 2020 Pakistan Medical Association. All rights reserved.eninfo:eu-repo/semantics/openAccessCopdGenetic SusceptibilityPlasminogen Activator Inhibitor-1 (Pai-1)PolymorphismsTissue-Type Plasminogen Activator (Tpa)Pai-1 and Tpa Gene Polymorphisms and Susceptibility To Chronic Obstructive Pulmonary Disease in a Sample of Turkish PopulationArticle7012 BQ4Q32310231533475534